Pharmaceuticals

A pill version of the popular GLP-1 weight-loss drug Wegovy has been green-lit for use in the U.S. Here’s what that means for health care

Popular supplements with billions of “good” microbes really help only a few illnesses, research shows

FDA officials are newly scrutinizing several approved therapies to treat RSV in babies despite the fact that these shots were shown to be safe in clinical trials

New WHO guidance calls for a worldwide obesity treatment “ecosystem” to ensure that GLP-1 weight-loss drugs are used fairly

Top-line results from two large clinical trials by Novo Nordisk, the company behind Ozempic and Wegovy, found oral semaglutide failed to slow down Alzheimer's progression

Melatonin supplements have become a ubiquitous sleep aid, but research shows that benefits are modest, and the heart health effects of long-term use are unknown

Deep emotional distress after birth kills many mothers. A new kind of drug offers better, faster treatment

A small study helps explain why some people taking Wegovy and similar weight-loss drugs cut back on alcohol, offering insight into potential new addiction therapies

Scientists look to genetics to explain why GLP-1 drugs work for some people but not for others

Less than 1 percent of clinical trials include pregnant or breastfeeding people. Experts say that needs to change

A new drug slows insulin-dependent diabetic deterioration and has sped up development of a complete remedy

The National Institutes of Health is investing $50 million into research on genetic and environmental factors underlying autism—news that was eclipsed by President Donald Trump’s recent controversial claims about acetaminophen